Cyklokapron
Cyklokapron
- In Australia, Cyklokapron (tranexamic acid) is TGA‑approved and is ordinarily prescription‑only and supplied by pharmacies with a prescription; while some community pharmacies or online sellers may sometimes dispense it without a receipt, this is not standard practice, may be inconsistent with local regulations and is not recommended — always consult a healthcare professional.
- Cyklokapron is used to reduce or prevent bleeding (surgical/trauma bleeding, heavy menstrual bleeding, dental procedures in haemophilia, epistaxis and other mucosal bleeds); it is an antifibrinolytic (a synthetic lysine analogue) that inhibits plasminogen binding and prevents fibrin clot breakdown.
- Typical adult doses: oral or IV 1,000–1,500 mg two to three times daily (heavy menstrual bleeding commonly 1,000–1,300 mg up to three times daily for up to 5 days); children are dosed by weight (about 10–15 mg/kg per dose two to three times daily); reduce dose or extend dosing interval in significant renal impairment.
- Available as 500 mg tablets (oral) and as injection concentrate (100 mg/mL, e.g. 1 g/10 mL ampoules or vials); administration is oral tablets, IV injection/infusion, and occasionally topical/local application for mucosal bleeds.
- Onset: IV administration works within minutes; oral dosing typically begins to have effect within about 1–2 hours.
- Duration: plasma half‑life is around 2–3 hours; clinical antifibrinolytic effects typically persist for approximately 8–12 hours depending on dose and route, which is why dosing is commonly two to three times daily.
- Alcohol: avoid excessive alcohol while taking Cyklokapron — alcohol can worsen dizziness, nausea and other side effects and is not recommended in combination with medications that increase thrombotic risk.
- The most common side effects are headache and nausea (other common effects include vomiting, diarrhoea, abdominal pain, back pain and dizziness); rare but serious risks include seizures, visual disturbances and thromboembolic events.
- Would you like to try “cyklokapron” without a prescription?
Basic Cyklokapron Information
- INN (International Nonproprietary Name): Tranexamic acid
- Brand Names Available In Australia: Cyklokapron (marketed by Pfizer) and generic tranexamic acid formulations
- ATC Code: B02AA02
- Forms & Dosages: 500 mg tablets; injection 100 mg/mL (ampoules/vials 5–10 mL / 10 mL)
- Manufacturers In Australia: Pfizer and multiple international generic suppliers (sourced via Australian distributors)
- Registration Status In Australia: TGA approved
- OTC / Rx Classification: Prescription only (Rx)
Latest Research Highlights
Patients and clinicians often ask whether tranexamic acid really reduces blood loss and transfusions.
Landmark international trials such as CRASH-2 and WOMAN underpin the strongest evidence for trauma and postpartum haemorrhage respectively.
Recent systematic reviews and randomised trials up to 2024 continue to support tranexamic acid as effective at reducing bleeding and transfusion needs in major surgery and trauma.
Australian audits and meta-analyses report shorter time to haemostasis and fewer transfusions when tranexamic acid is used perioperatively.
Safety signals in the literature highlight rare thromboembolic events and dose-related seizures with high intravenous doses.
Neonatal and breastfeeding safety data remain limited and are noted as research gaps.
| Indication | Typical Effect | Key Safety Notes |
|---|---|---|
| Trauma / Major Bleeding | Reduced blood loss and transfusion requirement reported in major trials and reviews | Rare thrombotic events; early IV dosing recommended in protocols |
| Postpartum Haemorrhage | Lower mortality from bleeding supported by large RCTs | Use under obstetric protocols; neonatal data limited |
| Major Surgery (perioperative) | Fewer transfusions and quicker haemostasis in audits and meta-analyses | Dose-related seizure risk with high IV doses; renal dosing considered |
| Heavy Menstrual Bleeding | Marked symptom improvement during treated cycles versus baseline | Short courses per cycle; monitor for thrombotic history |
Clinical Effectiveness In Australia
Patients commonly want to know whether treatment makes a practical difference in local hospitals.
Use in Australian tertiary centres and regional hospitals follows international evidence supporting reduced perioperative and obstetric bleeding when tranexamic acid is used.
TGA-approved oral and IV formulations include Cyklokapron 500 mg tablets and 100 mg/mL injection.
Local hospital audits report fewer transfusions and reduced intraoperative bleeding in orthopaedic, cardiac and gynaecological surgery when TXA protocols are applied.
PBS inclusion varies by indication and many outpatient uses are private prescriptions or hospital-supplied.
Primary care and telehealth prescribers commonly use oral 500 mg regimens for heavy menstrual bleeding with symptom improvement recorded over 3–5 days per cycle.
- Transfusion Reduction = percent decrease in transfusions reported in audits and reviews.
- Blood Loss = measured reduction in operative or menstrual blood loss versus control in clinical studies.
- Length Of Stay (LOS) = hospital days shortened in some surgical audits when TXA protocols used.
Indications And Expanded Uses
People ask what cyklokapron is commonly used for in everyday practice.
Approved and commonly used indications in Australia include heavy menstrual bleeding, perioperative bleeding prophylaxis for orthopaedic, ENT and cardiac surgery, trauma and postpartum haemorrhage protocols, and dental haemostasis in bleeding disorders.
Some specialised uses such as hereditary angioedema prophylaxis or topical nasal application for epistaxis are off‑label and guided by specialist practice.
Formulations on the Australian market are prescription-only 500 mg tablets and 100 mg/mL IV injections.
| Indication | Typical Adult Regimen | Notes |
|---|---|---|
| Heavy Menstrual Bleeding | 1,000–1,500 mg PO 2–3× daily for up to 5 days of menses | Short courses per cycle; check thrombotic history |
| Perioperative Bleeding Prophylaxis | 1,000–1,500 mg PO or IV 2–3× daily per protocol | Hospital protocols vary; start pre/intra-op as directed |
| Trauma / Postpartum Haemorrhage | IV dosing per local protocol; early administration advised | Used in emergency protocols in hospitals |
Pediatric dosing is weight-based at 10–15 mg/kg per dose 2–3× daily and renal impairment requires dose reduction or interval extension.
Composition And Brand Landscape
Patients often want brand and pack information before they order.
The active ingredient is tranexamic acid, an antifibrinolytic that inhibits plasminogen activation (ATC B02AA02).
Common brand names globally include Cyklokapron and Exacyl, plus generics; in Australia Cyklokapron is a marketed brand.
| Brand | Strength | Form | Manufacturer | Australian Availability |
|---|---|---|---|---|
| Cyklokapron | 500 mg; 100 mg/mL inj | Tablet; IV injection | Pfizer | TGA approved, prescription only |
| Generic Tranexamic Acid | 500 mg; 100 mg/mL inj | Tablet; IV injection | Multiple international manufacturers | Available via wholesalers and hospital supply |
Packaging commonly includes blister packs of 10–100 tablets and ampoules/vials for injection.
Not all pack sizes or indications are PBS-listed, so check the PBS website or ask your prescriber for subsidy status.
Contraindications And Special Precautions
People commonly worry about clotting, seizures and renal issues when starting tranexamic acid.
Absolute contraindications include known hypersensitivity, active intravascular clotting such as acute DVT or PE, history of convulsions or seizures, and acquired defective colour vision for injections.
Relative risks include renal impairment, prior thromboembolic disease, concurrent oestrogen-containing contraception, disseminated intravascular coagulation without specialist oversight, and concomitant factor concentrates.
- Absolute Contraindications: hypersensitivity; active thrombosis; history of seizures; acquired defective colour vision (injection).
- Relative Contraindications: renal impairment; prior thromboembolism; combined hormonal contraception; specialist oversight for DIC.
Special Australian considerations include checking creatinine clearance for elderly patients in residential aged care and using culturally safe communication with Aboriginal and Torres Strait Islander patients when discussing risks and benefits.
Pregnancy and lactation require specialist advice; postpartum haemorrhage protocols in hospitals use IV tranexamic acid when benefits outweigh risks.
Report suspected adverse reactions to the TGA via routine channels.
Dosage Guidelines
People often ask exactly how many tablets to take and for how long.
Marketed strengths in Australia are 500 mg tablets and 100 mg/mL injection.
| Indication | Route | Typical Adult Dose | Renal Adjustment |
|---|---|---|---|
| Heavy Menstrual Bleeding | Oral | 1,000–1,500 mg PO 2–3× daily for up to 5 days | Reduce dose or extend interval if CrCl <30 mL/min |
| Perioperative / Trauma | IV or Oral | Common IV protocol examples include 1 g IV single dose or repeated doses per local protocol | Adjust for reduced creatinine clearance |
| Pediatric | Oral/IV | 10–15 mg/kg per dose 2–3× daily | Weight-based dosing; adjust for renal function |
Elderly patients generally need no routine adjustment unless renal impairment is present.
Typical surgical and trauma courses are short-term and often under two weeks; menstrual use is limited to the menses days described.
Prescribers should follow local hospital protocols for high-risk cases and check PBS criteria for subsidised regimens.
Interactions Overview
Patients and pharmacists should review current medicines before dispensing tranexamic acid.
Major interaction concerns are additive thrombotic risk with pro‑thrombotic agents such as high‑dose oestrogens or tamoxifen and specialist oversight when used with systemic factor concentrates like prothrombin complex concentrate.
Drugs that lower the seizure threshold may increase rare seizure risk when combined with high intravenous TXA doses.
Renal‑cleared drugs or agents that affect renal function may alter TXA elimination and require monitoring.
- Pharmacist Checklist: confirm current medications; check renal function; ask about pregnancy status; review seizure history.
- Community pharmacists and telehealth prescribers should document counselling and query anticoagulant or combined hormonal contraception use before dispensing.
No notable food interactions are recorded, but counsel patients to avoid excessive alcohol when unwell and to report vomiting that could affect dosing.
Cultural Perceptions And Patient Habits
Many people want to know how Australians actually use and perceive cyklokapron.
Consumer discussions often praise rapid symptom relief for heavy periods and the low cost compared with surgical options.
Price sensitivity is common and patients frequently ask about PBS subsidy when seeking Cyklokapron.
Rural and remote patients commonly obtain oral prescriptions via telehealth and rely on local community pharmacies; intravenous formulations are hospital-supplied.
Clinicians should use culturally appropriate explanations and involve community health workers when treating Aboriginal and Torres Strait Islander patients.
- Trust In Pharmacists: many patients seek pharmacist advice before starting therapy.
- Reliance On PBS: subsidy questions are frequent and affect purchasing choices.
- Telehealth Access: common route for rural prescriptions for oral therapy.
- Rural Stock Limitations: plan ahead for repeat courses where supply can be delayed.
Availability And Pricing Patterns
Patients ask where to buy Cyklokapron and what it costs if not subsidised.
Tablets are commonly stocked in community pharmacies such as Chemist Warehouse, Priceline and TerryWhite Chemmart, and available from online pharmacies that accept e‑prescriptions.
Intravenous formulations are supplied to hospitals and accredited clinics rather than sold over the counter in community stores.
| Pharmacy Type | Availability | PBS / Private |
|---|---|---|
| Chemist Warehouse | Commonly stocks tablets for private prescription | Private pricing for many outpatient indications; check PBS for subsidy |
| Priceline | Stocked with pharmacist counselling | Private prescription for many uses; enquire about PBS eligibility |
| TerryWhite Chemmart | Available with pharmacist advice and local supply | Private prescription unless PBS-listed for indication |
| Online Pharmacies | Accept e‑prescriptions and deliver nationally | Private prescriptions common; verify subsidy status |
In our online pharmacy, cyklokapron is available without a prescription, with discreet delivery to Australia in 5-14 days.
Rural areas may face short-term stock constraints for tablets and delays in IV supply from hospitals, so plan ahead for repeat courses.
Comparable Medicines And Preferences
Clinicians often compare tranexamic acid with aminocaproic acid and topical haemostatic agents when choosing therapy.
Tranexamic acid is generally preferred for systemic bleeding control because of higher potency and extensive trial evidence across trauma, obstetrics and gynaecology.
| Medicine | Pros | Cons |
|---|---|---|
| Tranexamic Acid (TXA) | Strong RCT evidence, oral and IV forms, low cost | Rare seizure risk at high IV doses; renal adjustment required |
| Aminocaproic Acid (EACA) | Alternative if TXA unavailable | Less trial evidence; larger doses often required |
| Topical Haemostatic Agents | Useful for local bleeding such as epistaxis or dental sockets | Limited systemic benefit for major bleeding |
Hospital formularies in Australia typically prefer tranexamic acid for systemic indications and community prescribers choose oral TXA for heavy menstrual bleeding.
Always consult the TGA‑listed product information and local hospital guidelines when selecting alternatives.
FAQ
- Q: Is Cyklokapron available without a prescription in Australia?
- A: Officially tranexamic acid is prescription-only in Australia, though some online services may offer different purchasing options; check regulatory status and prescriber advice.
- Q: Will the PBS cover tranexamic acid for heavy periods?
- A: PBS listing depends on the indication and schedule; patients should check the PBS website or ask their prescriber or pharmacist for current subsidy information.
- Q: Can I take tranexamic acid with my contraceptive pill?
- A: Concomitant use is common but caution is advised if there is an existing thrombotic risk; discuss with your prescriber.
- Q: What symptoms should prompt urgent care?
- A: Seek urgent care for visual changes, sudden limb pain or swelling, shortness of breath, or any seizure activity.
Guidelines For Proper Use
Patients want clear, practical instructions they can follow at home.
Pharmacist counselling should confirm the indication, review renal function and seizure or thrombotic history, reconcile current medications, and explain the dosing schedule clearly.
For oral tablets the usual advice for heavy periods is 1,000–1,500 mg PO two to three times daily during the heavy days of menses for up to five days.
Advise patients not to double a missed dose and to stop and seek medical attention for signs of thrombosis or neurological symptoms such as seizures.
Store tablets below 25°C and keep injections protected from light as per product information.
- Pharmacist Checklist: verify prescription; check creatinine clearance; review anticoagulant or hormonal therapy; document counselling; provide cultural communication where needed.
- Patient Handout Points: dosing schedule, duration for menses, missed dose instructions, when to seek urgent care, storage advice.
For IV use follow hospital protocols for administration and monitoring and refer to TGA and local hospital guidance for specialised scenarios.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-7 days |
| Wollongong | New South Wales | 5-7 days |
| Geelong | Victoria | 5-7 days |
| Hobart | Tasmania | 5-9 days |
| Darwin | Northern Territory | 5-9 days |
| Cairns | Queensland | 5-9 days |
| Townsville | Queensland | 5-9 days |
| Sunshine Coast | Queensland | 5-7 days |